CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


UTTR1147A-matched PlaceboWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2583 UTTR1147A Wiki 1.00
drug1420 MSTT1041A-matched Placebo Wiki 1.00
drug1419 MSTT1041A Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia

This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) or UTTR1147A in combination with standard of care (SOC) compared with matching placebo in combination with SOC in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.

NCT04386616 COVID-19 Pneumonia Drug: MSTT1041A Drug: MSTT1041A-matched Placebo Drug: UTTR1147A Drug: UTTR1147A-matched Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Clinical Status, Assessed Using a 7-Category Ordinal Scale

Time: Day 28

Secondary Outcomes

Measure: Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of ≤2 Maintained for 24 hours

Time: Up to 60 days

Measure: Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

Time: From Baseline up to 60 days

Measure: Incidence of Mechanical Ventilation

Time: Up to 60 days

Measure: Ventilator-Free Days

Time: Up to 28 days

Measure: Incidence of Intensive Care Unit (ICU) Stay

Time: Up to 60 days

Measure: Duration of ICU Stay

Time: Up to 60 days

Measure: Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)

Time: Up to 60 days

Measure: Mortality Rate at Days 7, 14, 21, 28, and 60

Time: Days 7, 14, 21, 28, and 60

Measure: Time to Hospital Discharge or "Ready for Discharge"

Time: Up to 60 days

Measure: Duration of Supplemental Oxygen

Time: Up to 60 days

Measure: Duration of Hypoxemia

Time: Up to 60 days

Measure: Percentage of Participants Alive and Free of Respiratory Failure

Time: Day 28

Measure: Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

Time: Up to 60 days

Measure: Change from Baseline in Respiratory Rate

Time: From Baseline up to 60 days

Measure: Change from Baseline in Pulse Rate

Time: From Baseline up to 60 days

Measure: Change from Baseline in Systolic Blood Pressure

Time: From Baseline up to 60 days

Measure: Change from Baseline in Diastolic Blood Pressure

Time: From Baseline up to 60 days

Measure: Change from Baseline in Body Temperature

Time: From Baseline up to 60 days

Measure: Change from Baseline in Oxygen Saturation

Time: From Baseline up to 60 days

Measure: Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)

Time: From Baseline up to 60 days

Measure: Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)

Time: From Baseline up to 60 days

Measure: Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters

Time: From Baseline up to 60 days

Measure: Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters

Time: From Baseline up to 60 days

Measure: Serum Concentration of UTTR1147A at Specified Timepoints

Time: At predefined timepoints from Baseline until Study Completion (up to 60 days)

Measure: Serum Concentration of MSTT1041A at Specified Timepoints

Time: At predefined timepoints from Baseline until Study Completion (up to 60 days)

Measure: Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study

Time: From Baseline up to 60 days


Related HPO nodes (Using clinical trials)